Vemlidy’s price 4.7% ↓...Vemliver’s voluntarily 12.6% ↓

Price of 2 items whose PVA term expired will be cut from the 1st of next month

Companies opt to reduce the price by a single-digit rate for each strength of their baraclude product

Gilead’s adult chronic hepatitis B treatment, ‘Vemlidi Tab (tenofovir ala fenamide) will be subject to Price-Volume Agreement price cuts and be sold at a 4.7% lower price starting next month.

 

Daewoong Pharmaceutical opted to reduce the price of its latecomer Vemliver Tab by 12.6%.

 

According to industry sources on the 21st, the Ministry of Health and Welfare (MOHW) ‘Amendment to the drug reimbursement list and reimbursement ceiling price table’ contains the abovementioned changes that will become effective as of the 1st of next month.

 

◆Price cut for PVA drugs = The PVA price cut will be applied to two products next month, and the two drugs underwent PVA negotiations with the National Health Insurance Service, one as a Price-volume agreement type ‘A’ and the other as a Price-volume agreement type ‘B’ drug.

 

First, the drug that completed negotiations as a PVA Type A drug was Abbvie’s Rinvoq (upadacitinib), and its price will be reduced by 0.9%.

 

Among new drugs listed as negotiable after the introduction of the drug price negotiation system, the government applies PVA A type to drugs whose claims amount in the same product category exceeds the expected claims amount by over 30%.

 

By same product category, drugs that have the same company name, route of administration, ingredient, and formulation are classified as drugs of the same product category.’ The drug subject to ‘Type B’ price reduction was Gilead’s Vemlidy Tab, and its price was cut by 4.7%.

 

The government applies PVA Type B and reduces the price of drugs ▲whose price ceiling had been already adjusted according to Type A, ▲ whose claims amount increased by over 60% from the previous year without undergoing Type A negotiations, or 4 years after receiving Type A negotiations, or ▲ has increased by over 10% but the increased amount exceeds KRW 5 billion and does not fall under PVA Type A.

 

◆Products that submitted voluntary price cuts= Five products in total decided to make voluntary price cuts.

 

When a pharmaceutical company submits a request to lower its drug price to an amount lower than the ceiling price set for the product, the government adjusts the insurance drug price of the product to the requested amount.

 

One voluntary price cut for a latecomer drug was made in line with the PVA price cut of Vemlidy.

 

Daewoong Pharmaceutical opted to make a double-digit reduction in the price of its latecomer Vemliver Tab, by 12.6%.

 

BMS Korea decided to make a price cut in the 1% range for each of its dosage strengths of Baraclude (entecavir).

 

Janssen Korea’ made a voluntary price cut of 0.5% each for its Tremfya Prefilled Syringe (guselkumab) and Tremfya Autoinjection Inj.